Tyrosine Kinases / Adaptors
| CSTコード |
包装 |
希望納入価格 (円) |
国内在庫  |
ご登録代理店情報 カスタマー情報にご登録いただいた代理店を表示しています。
ご登録代理店の変更は こちら。 |
| #2256S | 100 μL | 46,000 | |
|
EGFR抗体製品一覧
2256 の推奨プロトコール
最適な結果を得るために：Cell Signaling Technology (CST) 社は、各製品の推奨プロトコールを使用することを強くお薦めいたします。
推奨プロトコールはCST社内試験の徹底的なバリデーションに基づいて作成されておりますので、正確かつ再現性の高い結果が得られます。
注：各製品に最適化されたプロトコールをリンクしています。
| | |
-
2256:
-
Immunoprecipitation
| 特異性・感度 | |
| 内在性レベルのEGF Receptor タンパク質を検出します。他のEGFR ファミリータンパク質とは交差しません。 |
| 使用抗原 | |
| ヒトの組換えEGFR タンパク質の細胞外ドメイン |
Western Blotting
Western blot analysis of EGF Receptor (EGFR1) Mouse mAb (IP Specific) immunoprecipitated samples from Iressa-treated and untreated HCC827 cell lysates, using Phospho-EGF Receptor (Tyr1068) Antibody (#2234) (upper) and EGF Receptor Antibody (#2232) (lower).
The epidermal growth factor (EGF) receptor is a transmembrane tyrosine kinase that belongs to the HER/ErbB protein family. Ligand binding results in receptor dimerization, autophosphorylation, activation of downstream signaling, internalization, and lysosomal degradation (1,2). Phosphorylation of EGF receptor (EGFR) at Tyr845 in the kinase domain is implicated in stabilizing the activation loop, maintaining the active state enzyme, and providing a binding surface for substrate proteins (3,4). c-Src is involved in phosphorylation of EGFR at Tyr845 (5). The SH2 domain of PLCγ binds at phospho-Tyr992, resulting in activation of PLCγ-mediated downstream signaling (6). Phosphorylation of EGFR at Tyr1045 creates a major docking site for the adaptor protein c-Cbl, leading to receptor ubiquitination and degradation following EGFR activation (7,8). The GRB2 adaptor protein binds activated EGFR at phospho-Tyr1068 (9). A pair of phosphorylated EGFR residues (Tyr1148 and Tyr1173) provide a docking site for the Shc scaffold protein, with both sites involved in MAP kinase signaling activation (2). Phosphorylation of EGFR at specific serine and threonine residues attenuates EGFR kinase activity. EGFR carboxy-terminal residues Ser1046 and Ser1047 are phosphorylated by CaM kinase II; mutation of either of these serines results in upregulated EGFR tyrosine autophosphorylation (10).
-
Hackel, P.O. et al. (1999) Curr Opin Cell Biol 11, 184-9.
-
Zwick, E. et al. (1999) Trends Pharmacol Sci 20, 408-12.
-
Cooper, J.A. and Howell, B. (1993) Cell 73, 1051-4.
-
Hubbard, S.R. et al. (1994) Nature 372, 746-54.
-
Biscardi, J.S. et al. (1999) J Biol Chem 274, 8335-43.
-
Emlet, D.R. et al. (1997) J Biol Chem 272, 4079-86.
-
Levkowitz, G. et al. (1999) Mol Cell 4, 1029-40.
-
Ettenberg, S.A. et al. (1999) Oncogene 18, 1855-66.
-
Rojas, M. et al. (1996) J Biol Chem 271, 27456-61.
-
Feinmesser, R.L. et al. (1999) J Biol Chem 274, 16168-73.
PhosphoSitePlus®：
